Immunoglobulin Light-chain Amyloidosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Myocardial perfusion in cardiac amyloidosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Amyloidosis2
- Cardiomyopathies2
- Coronary Circulation1
- Heart Failure1
- Prealbumin1
Leading journals2
- European journal of heart failure1
- JAMA1
Leading researchers8
- Brown J1
- Chacko L1
- Fontana M1
- Gilbertson J1
- Gillmore J1
- González A1
- Hawkins P1
- Ioannou A1
Affiliations (unnormalised)6
- Alma Mater Studiorum University of Bologna1
- Amyloidosis Center1
- Barts Heart Centre1
- Boston University Chobanian & Avedisian School of Medicine1
- Columbia University Irving Medical Center1
- Institute of Cardiovascular Science1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
A nonproliferative disorder of PLASMA CELLS characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.